Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03435861
Other study ID # RC31/16/8371
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 8, 2018
Est. completion date June 30, 2021

Study information

Verified date June 2023
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

For this project, neflamapimod and placebo will be provided free of charge by the EIP company (www.eippharma.com). Neflamapimod is currently tested in 2 clinical trials in AD, one in Europe (The Netherlands) and one in the USA (clinical trials.gov/VX-745). The company commenced in May 2015 dosing in two phase 2a clinical studies in patients with Early AD: one in the Netherlands that is focused on PET amyloid imaging as the primary biomarker of drug effect, and one in the US (California) that is focused on Cerebrospinal fluid (CSF) evaluation to determine CSF drug concentrations and effects on inflammatory markers and disease biomarkers. Pharmacokinetic evaluation in these patients has demonstrated blood drug concentration levels in the predicted therapeutic range; and importantly, the data from the US study demonstrate that the drug achieves target drug concentrations in CSF, thus confirming the drug robustly enters the brain in humans. The present project offers us a unique chance to test this promising drug in AD patients. The aim of the study is to focus on PET neuroinflammation imaging as the primary biomarker of this drug effect. The chosen biomarker for imaging neuroinflammation in patients is [1 8F]-DPA714.


Description:

The present project is an intervention proof of concept study to test the efficacy of neflamapimod in a population of AD patients at an early stage. To track the impact of this drug in patients, the investigators will use an innovative radiotracer, [18F]DPA-714, as a promising ligand of microglial activation targeting the translocator protein (TSPO), specific of microglial activation. The use of [18F]DPA-714 will allow to monitor the evolution of neuroinflammation in patients as a function of treatment. The main objective will be to compare the level of inflammation using the [18F]DPA-714 in neflamapimod and placebo groups after 12 weeks of treatment. Blood and cerebrospinal fluid (CSF) samples and magnetic resonance imaging (MRI) will also be collected to assess inflammation markers and brain structure respectively in these patients.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date June 30, 2021
Est. primary completion date April 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - A group of 40 AD patients at an early stage (prodromal) will be recruited. Patient's recruitment will follow the most recent research criteria for AD in its "typical form" (Dubois, Feldman et al. 2014): - Age 50 - 90 (inclusive) - Willing and able to provide informed consent - Objective memory impairment corroborated by level of performance on a standardized memory test (Free and Cued Selective Reminding test, (Grober, Hall et al. 2008)) < -1.5 DS according to established norms and - Documented cerebral amyloidopathy using CSF analysis or PET amyloid imaging and - Early stage of the disease (Mini Mental State Examination > 20) (Folstein, Robins et al. 1983). Exclusion Criteria: - • Evidence of neurodegenerative disease other than AD - Inability for any reason to undergo MRI scans (e.g. pacemaker). Patients who require sedation for screening procedures such as MRI may receive a short-acting sedative. - Psychiatric disorder that would compromise ability to comply with study requirements - History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years - Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder or metabolic/endocrine disorders or other disease that would preclude treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy - Recent (<60 days) changes to AD medications prescribed for cognitive reasons or with the potential to impact cognition - Psychotropic drugs taken within 1 month. Anticoagulant drugs taken within 1 week. - Participation in a study of an investigational drug less than 6 months or 5 half-lives of the investigational drug, whichever is longer, before enrollment in the study - Male subjects with female partner of child-bearing potential who are unwilling or unable to adhere to contraception requirements - Female subjects who have not reached menopause or have not had a hysterectomy or bilateral oophorectomy/salpingoophorectomy - Positive urine or serum pregnancy test or plans desires to become pregnant during the course of the trial - History of alcohol and/or illicit drug abuse within 6 months. - Infection with hepatitis A, B or C or HIV. - Any factor deemed by the investigator to be likely to interfere with study conduction

Study Design


Intervention

Drug:
VX-745
active drug capsules
placebo
placebo capsules

Locations

Country Name City State
France CHU Toulouse Toulouse

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Toulouse Fondation Plan Alzheimer

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV) To track the impact of this drug in patients, investigators will use an innovative radiotracer, [18F]DPA-714, as a promising ligand of microglial activation targeting the translocator protein (TSPO), specific of microglial activation. The use of [18F]DPA-714 will allow us to monitor the evolution of neuroinflammation in patients as a function of treatment. the main objective will be to compare the level of inflammation using the [18F]DPA-714 in neflamapimod and placebo.
Regional cortical DPA-714 mean SUV will be measured in each subject using a Matlab (The MathWorks®) script. Mean global SUVs will be calculated
3 month
Primary brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV) 2 SUVs in the five lobes will be calculated. 3 month
Primary brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV)3 SUVs in specific regions of interest (ROIs: orbitofrontal, anterior cingulate, posterior cingulate and precuneus) will be calculated. 3 month
Secondary Neuropsychological assessment to assess the following cognitive functions 1: Memory: Rey Figure 3 month
Secondary Neuropsychological assessment to assess the following cognitive functions 2: Memory: DMS 48, 3 month
Secondary Neuropsychological assessment to assess the following cognitive functions 1.1: Language: confrontation naming (Gremots), 3 month
Secondary Neuropsychological assessment to assess the following cognitive functions 2.2: Language: FAS fluencies, 3 month
Secondary Neuropsychological assessment to assess the following cognitive functions 3: o Attention and executive functions: D2 3 month
Secondary Neuropsychological assessment to assess the following cognitive functions 4: o Attention and executive functions: TEA 3 month
Secondary Neuropsychological assessment to assess the following cognitive functions 5: o Attention and executive functions: SDMT WAIS 3 month
Secondary Blood and CSF biomarkers of inflammation1 ApoE phenotype 3 month
Secondary Blood and CSF biomarkers of inflammation 2 TSPO phenotype, 3 month
Secondary Blood and CSF biomarkers of inflammation 3 TNFa, 3 month
Secondary Blood and CSF biomarkers of inflammation 4 IL-1b, 3 month
Secondary Blood and CSF biomarkers of inflammation 5 IFNg 3 month
Secondary Blood and CSF biomarkers of inflammation 6 IL-12 3 month
Secondary Blood and CSF biomarkers of inflammation 7 IFNa/b 3 month
Secondary Blood and CSF biomarkers of inflammation 8 IL-10 3 month
Secondary Blood and CSF biomarkers of inflammation 9 IL-6 3 month
Secondary Blood and CSF biomarkers of inflammation 10 IL-8, 3 month
Secondary Blood and CSF biomarkers of inflammation 11 MCP-1, 3 month
Secondary Blood and CSF biomarkers of inflammation 12 GM-CSF 3 month
Secondary Blood and CSF biomarkers of inflammation 13 IL-27 3 month
Secondary Blood and CSF biomarkers of inflammation 14 chimiokines receptors, 3 month
Secondary Blood and CSF biomarkers of inflammation 15 PD-1, 3 month
Secondary Blood and CSF biomarkers of inflammation 16 CD14/16 3 month
Secondary Blood and CSF biomarkers of inflammation 17 p-tau, 3 month
Secondary Blood and CSF biomarkers of inflammation 18 abéta42, 3 month
Secondary Blood and CSF biomarkers of inflammation 19 Abeta40, 3 month
Secondary Blood and CSF biomarkers of inflammation 20 cells count 3 month
Secondary Blood and CSF biomarkers of inflammation 21 TNFa 3 month
Secondary Blood and CSF biomarkers of inflammation 22 IL-1b 3 month
Secondary Blood and CSF biomarkers of inflammation 23 IL-12 3 month
Secondary Blood and CSF biomarkers of inflammation 24 MCP-1 3 month
Secondary Blood and CSF biomarkers of inflammation 25 GM-CSF 3 month
Secondary Blood and CSF biomarkers of inflammation 26 IL-27, 3 month
Secondary Blood and CSF biomarkers of inflammation 27 PD-1 3 month
Secondary Blood and CSF biomarkers of inflammation 28 CD14/16 3 month
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A